Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos N Papandreou

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Biomolecules|June 28, 2014
The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate CancerPanagiotis J Vlachostergios, Christos N Papandreou
Frontiers in Oncology|February 21, 2015
Targeting neuroendocrine prostate cancer: molecular and clinical perspectivesPanagiotis J Vlachostergios, Christos N Papandreou
Journal of Cell Communication and Signaling|March 16, 2013
The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?Panagiotis J Vlachostergios, Christos N Papandreou
Archives of Medical Science : AMS|May 22, 2015
Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysisPanagiotis J Vlachostergios, Christos N Papandreou
World Journal of Experimental Medicine|February 13, 2014
Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?Panagiotis J Vlachostergios, Christos N Papandreou
Cancer Research|August 4, 2004
Bortezomib as a potential treatment for prostate cancerChristos N Papandreou, Christopher J Logothetis
Journal of Pediatric Hematology/Oncology|January 7, 2010
Is methylation the key to CD10 loss?Christos N Papandreou, David M Nanus
Urologic Oncology|June 29, 2010
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistanceIoannis A Voutsadakis, Christos N Papandreou
EMBO Molecular Medicine|April 13, 2012
Selecting for predisposition to cancer cachexiaIoannis Gioulbasanis, Panagiotis J Vlachostergios, Christos N Papandreou
Neurological Research|April 9, 2013
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53Panagiotis J Vlachostergios, Eleana Hatzidaki, Christos N Papandreou
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Biomolecules|June 28, 2014
The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate CancerPanagiotis J Vlachostergios, Christos N Papandreou
Frontiers in Oncology|February 21, 2015
Targeting neuroendocrine prostate cancer: molecular and clinical perspectivesPanagiotis J Vlachostergios, Christos N Papandreou
Journal of Cell Communication and Signaling|March 16, 2013
The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?Panagiotis J Vlachostergios, Christos N Papandreou
Archives of Medical Science : AMS|May 22, 2015
Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysisPanagiotis J Vlachostergios, Christos N Papandreou
World Journal of Experimental Medicine|February 13, 2014
Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?Panagiotis J Vlachostergios, Christos N Papandreou
Cancer Research|August 4, 2004
Bortezomib as a potential treatment for prostate cancerChristos N Papandreou, Christopher J Logothetis
Journal of Pediatric Hematology/Oncology|January 7, 2010
Is methylation the key to CD10 loss?Christos N Papandreou, David M Nanus
Urologic Oncology|June 29, 2010
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistanceIoannis A Voutsadakis, Christos N Papandreou
EMBO Molecular Medicine|April 13, 2012
Selecting for predisposition to cancer cachexiaIoannis Gioulbasanis, Panagiotis J Vlachostergios, Christos N Papandreou
Neurological Research|April 9, 2013
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53Panagiotis J Vlachostergios, Eleana Hatzidaki, Christos N Papandreou
Pageof 6